Trial Profile
Pembrolizumab (MK-3475) and Epacadostat (INCB024360) in Thymic Carcinomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
- 28 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 15 Mar 2018 Status changed from active, no longer recruiting to recruiting.
- 25 Jan 2018 Results (n=41) assessing the activity of pembrolizumab, a monoclonal antibody that targets PD-1, in patients with advanced thymic carcinoma, were published in the Lancet Oncology.